Steve Morris

Steve joined Biomea Fusion as Chief Medical Officer in February 2022, after having served as a clinical consultant since 2020. He brings over 35 years of experience as a physician-scientist and life sciences executive. Notably, Dr. Morris served on the staff at St. Jude Children’s Research Hospital for 25 years. In addition to working as a clinician, he led a basic and translational research laboratory at St. Jude, which discovered and characterized oncogenes that cause a variety of human cancers, most notably anaplastic lymphoma kinase (ALK). Prior to joining full time, Dr. Morris has served as a consultant or CMO for multiple oncology-focused biotech startups, including Biomea. Steve is a member of the medical honor society Alpha Omega Alpha, an American Society of Clinical Oncology Young Investigator Award winner, and an inductee into the American Society for Clinical Investigation. Dr. Morris earned his MD from Louisiana State University Health Science Center, completed an internal medicine residency at the University of Texas Southwestern Health Science Center, and completed training in medical oncology at Yale University School of Medicine.